UCB presents new gMG management data at 2024 AANEM and MGFA meetings

UCB, a prominent global biopharmaceutical firm, is set to present extensive findings from its generalized myasthenia gravis (gMG) portfolio at the upcoming American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) annual meeting and the Myasthenia Gravis Foundation of America (MGFA) Scientific Session. This event is scheduled to occur from October 15 to 18, 2024, at the Savannah Convention Center in Georgia, USA.

UCB will showcase a total of 14 scientific presentations, including one oral presentation, which will highlight new data from their recently approved gMG treatments, RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ® (zilucoplan). These presentations will span findings from both clinical trials and real-world studies, focusing on clinical outcomes and patient experiences in managing gMG.

Manuela Maronati, Global Asset Head of Neuroimmunology & Rare at UCB, emphasized the company's commitment to revolutionizing the lives of individuals with generalized myasthenia gravis through continuous innovation and in-depth clinical research. She noted that the data presented at the 2024 AANEM Annual Meeting and MGFA Scientific Session underscores UCB's dedication to enhancing the understanding and treatment of this complex condition. Maronati expressed particular excitement about the insights from their RAISE-XT and MycarinG studies, which demonstrate significant advancements in gMG management.

Key presentations by UCB at the events will include:
- An oral presentation detailing UCB's efforts to improve global education standards for myasthenia gravis.
- Results from a Phase 3b study on transitioning from intravenous complement component 5 inhibitors to subcutaneous zilucoplan in myasthenia gravis patients.
- Data from the RAISE-XT trial for zilucoplan, featuring an interim analysis of long-term safety and efficacy over up to 120 weeks. This includes adherence to daily self-administered subcutaneous zilucoplan and a post-hoc analysis of corticosteroid sparing and non-steroidal immunosuppressant therapy adjustments.
- Post hoc analyses from the Phase 3 MycarinG trial for rozanolixizumab, which examine the impact of treatment on specific muscle group weaknesses, evaluate its efficacy in patients aged 65 and older, and highlight its use for tailored treatment regimens.

Additionally, UCB will host an industry-sponsored therapeutic update session on October 16, 2024, led by experts discussing treatment options for generalized myasthenia gravis. Emmanuel Caeymaex, Executive Vice President and Head of Patient Impact at UCB, highlighted the importance of these presentations in advancing global education standards for gMG and reaffirmed UCB's commitment to supporting healthcare professionals with valuable knowledge and tools.

During the AANEM and MGFA 2024 events, UCB will also provide a series of sponsored scientific and therapeutic updates for registered healthcare professionals. Attendees are encouraged to visit UCB's booth for more information.

UCB's participation in these significant medical meetings underscores their leadership in neuromuscular research and their ongoing efforts to improve the therapeutic landscape for patients with generalized myasthenia gravis. The data presented will not only enhance the understanding of gMG but also spotlight the potential benefits and management strategies associated with UCB's innovative treatments, ZILBRYSQ® and RYSTIGGO®.